Now ideas for wellness

About Meiji

At a Glance

At a Glance

Get to know Meiji at a glance – from our core business to our most important numbers.

Food

Our Nutrition Initiatives

Our Nutrition Initiatives

Our goal is to improve the lives of people of all ages around the world through nutrition, from infants to older adults, and we are dedicated to achieving this goal.

Pharmaceuticals

R&D

Medical needs are always diversifying – here's how Meiji is responding.

Year in Review

Year ended March 2023

Key Figures

Net Sales
¥1,062.1billion
4.8%
Operating Income
¥75.4billion
18.8%
Operating Income Ratio
7.1%
2.1percentage points
ROE
10.0%
3.5percentage points
Capital Expenditures
¥72.1billion
R&D Expenses
¥30.9billion

Breakdown by Segment

  • Food
  • Pharmaceuticals

Net Sales

Operating Income

Business Performance Analysis

Food
Net Sales
¥865.6billion
4.8%
Operating Income
¥55.8billion
26.5%
Income Analysis(Billions of yen)
Pharmaceuticals
Net Sales
¥197.2billion
4.9%
Operating Income
¥21.7billion
16.4%
Income Analysis(Billions of yen)

Capital Expenditures

  • Food
  • Pharmaceuticals

Food

¥63.4billion

Pharmaceuticals

¥8.5billion

Cash Dividends per Share / Dividend Payout Ratio

  • Cash Dividends per Share
  • Dividend Payout Ratio

Future Prospects

This is our Medium-term Business Plan,
FYE 3/2022 through FYE 3/2024.

FYE3/2022
Results
FYE3/2023
Results
FYE3/2024
Plan
FYE3/2024
Targets
(Initial plan)
Net sales ¥1,013.0 biliion ¥1,062.1 biliion ¥1,098.5 biliion ¥1,080.0 biliion
Operating income ¥92.9 billion ¥75.4 billion ¥80.0 billion ¥120.0 billion
Operating income ratio 9.2% 7.1% 7.3% 11.1%
ROE 13.5% 10.0% 7.0% 11.0%
as of May 11, 2023 as of May 18, 2021

The Accounting Standard for Revenue Recognition is applied from FYE 3/2022. As such, the above figures are calculted based on assumption of accounting treatment changes related to revenue recognition.